Dermira (DERM) Gets a Hold Rating from Mizuho Securities


In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Hold rating on Dermira (DERM), with a price target of $9. The company’s shares opened today at $7.83, close to its 52-week low of $6.00.

According to TipRanks.com, Koffler is a 4-star analyst with an average return of 7.7% and a 39.8% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Assertio Therapeutics Inc, and Eagle Pharmaceuticals Inc.

Dermira has an analyst consensus of Moderate Buy, with a price target consensus of $15.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $27.42 and a one-year low of $6.00. Currently, Dermira has an average volume of 644.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Dermira, Inc. is a biopharmaceutical company, which engages in the provision of biotech ingenuity to medical dermatology. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis, and acne.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts